PBS (without Mg²⁺ and Ca²⁺) pH7.4, 150mM NaCl, 50% Glycerol
0.02% Sodium azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Batch dependent (Please refer to the vial label for the specific concentration.)
The antiserum was produced against synthesized peptide derived from human p53 (336-385).
Purified by antigen-affinity chromatography. Non-acetylated peptide was removed by chromatography using corresponding non-acetylated peptide.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
BCC7 , LFS1 , P53 , TP53 , TRP53 , tumor protein p53 , p53
Cytoplasm,Nucleus,Nucleus,PML body,Endoplasmic reticulum,Mitochondrion matrix,Nucleus,Cytoplasm,Nucleus,Cytoplasm,Nucleus,Cytoplasm,Nucleus,Cytoplasm,Nucleus,Cytoplasm,Nucleus,Cytoplasm,Cytoplasm
This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons (PMIDs: 12032546, 20937277). [provided by RefSeq, Feb 2013]